Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects

Clinical Pharmacology and Therapeutics

Volumn 102, Issue 4, 2017, Pages 688-700

  Zhou, Y ^a   Ingelman Sundberg, M ^a   Lauschke, V M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; TRANSCRIPTION FACTOR GATA 4;

AFRICAN; ALLELE; ARTICLE; ASIAN; DRUG METABOLISM; EAST ASIAN; EUROPEAN; GENE FREQUENCY; GENE LOCUS; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MISSENSE MUTATION; PREVALENCE; PRIORITY JOURNAL; SOUTH ASIAN; SPLICING DEFECT; WHOLE EXOME SEQUENCING; WHOLE GENOME SEQUENCING; ANCESTRY GROUP; COPY NUMBER VARIATION; GENETICS; META ANALYSIS; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 ENZYME SYSTEM; DNA COPY NUMBER VARIATIONS; HAPLOTYPES; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 85019668677     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.690     Document Type: Article

References (50)

1. Lauschke, V.M. & Ingelman–Sundberg, M. The importance of patient-specific factors for hepatic drug response and toxicity. Int. J. Mol. Sci. 17, E1714 (2016).
2. Eichelbaum, M., Ingelman–Sundberg, M. & Evans, W.E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119–137 (2006).
3. Bertz, R.J. & Granneman, G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32, 210–258 (1997).
4. Evans, W.E. & Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487–491 (1999).
5. Phillips, K.A., Veenstra, D.L., Oren, E., Lee, J.K. & Sadee, W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286, 2270–2279 (2001).
6. Fujikura, K., Ingelman–Sundberg, M. & Lauschke, V.M. Genetic variation in the human cytochrome P450 supergene family. Pharmacogenet. Genomics 25, 584–594 (2015).
7. Lauschke, V.M. & Ingelman–Sundberg, M. Requirements for comprehensive pharmacogenetic genotyping platforms. Pharmacogenomics 17, 917–924 (2016).
8. Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–424 (2015).
9. Sim, S.C. & Ingelman–Sundberg, M. The human cytochrome P450 (CYP) allele nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum. Genomics 4, 278–281 (2010).
10. McGraw, J. & Waller, D. Cytochrome P450 variations in different ethnic populations. Expert Opin. Drug Metab. Toxicol. 8, 371–382 (2012).
11. Zanger, U.M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103–141 (2013).
12. 1000 Genomes Project Consortium et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
13. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).
14. Krishnakumar, D. et al. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population. Fundam. Clin. Pharmacol. 26, 295–306 (2012).
15. Roco, A. et al. Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the Chilean population: comparison with Caucasian and Asian populations. Front. Genet. 3, 229 (2012).
16. Zanger, U.M., Klein, K., Saussele, T., Blievernicht, J., Hofmann, M.H. & Schwab, M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8, 743–759 (2007).
17. Sim, S.C. et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79, 103–113 (2006).
18. Mwinyi, J. et al. The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression. Life Sci. 86, 699–706 (2010).
19. Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F. & Ingelman–Sundberg, M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 278, 441–446 (1996).
20. Gaedigk, A., Sangkuhl, K., Whirl–Carrillo, M., Klein, T. & Leeder, J.S. Prediction of CYP2D6 phenotype from genotype across world populations. Genet. Med. 19, 69–76 (2017).
21. Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383–391 (2001).
22. Williams, J.A. et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos. 30, 883–891 (2002).
23. Fricke–Galindo, I. et al. Interethnic variation of CYP2C19 alleles, “predicted” phenotypes and “measured” metabolic phenotypes across world populations. Pharmacogenomics J. 16, 113–123 (2016).
24. Kalman, L.V. et al. Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting. Clin. Pharmacol. Ther. 99, 172–185 (2016).
25. Griese, E.U., Asante–Poku, S., Ofori–Adjei, D., Mikus, G. & Eichelbaum, M. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics 9, 715–723 (1999).
26. Dandara, C., Swart, M., Mpeta, B., Wonkam, A. & Masimirembwa, C. Cytochrome P450 pharmacogenetics in African populations: implications for public health. Expert Opin. Drug Metab. Toxicol. 10, 769–785 (2014).
27. Bains, R.K. et al. Molecular diversity and population structure at the cytochrome P450 3A5 gene in Africa. BMC Genet. 14, 34 (2013).
28. Tyndale, R.F. & Sellers, E.M. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab. Dispos. 29(4 Pt 2), 548–552 (2001).
29. Ariyoshi, N. et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol. Biomarkers Prev. 11, 890–894 (2002).
30. Ward, B.A., Gorski, J.C., Jones, D.R., Hall, S.D., Flockhart, D.A. & Desta, Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306, 287–300 (2003).
31. Ogburn, E.T., Jones, D.R., Masters, A.R., Xu, C., Guo, Y. & Desta, Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos. 38, 1218–1229 (2010).
32. Sarfo, F.S. et al. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J. Antimicrob. Chemother. 69, 491–499 (2014).
33. Rotger, M. et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 15, 1–5 (2005).
34. Pinillos, F. et al. Case report: severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation. BMC Infect. Dis. 16, 56 (2016).
35. Desta, Z. et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8, 547–558 (2007).
36. Burger, D. et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br. J. Clin. Pharmacol. 61, 148–154 (2006).
37. Gréen, H. et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin. Pharmacol. Toxicol. 104, 130–137 (2009).
38. Hertz, D.L. et al. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann. Oncol. 24, 1472–1478 (2013).
39. Franco, V. & Perucca, E. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Expert Opin. Drug Metab. Toxicol. 11, 1269–1279 (2015).
40. Johnson, J.A. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625–629 (2011).
41. Pirmohamed, M. et al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369, 2294–2303 (2013).
42. Kawanishi, C., Lundgren, S., Agren, H. & Bertilsson, L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur. J. Clin. Pharmacol. 59, 803–807 (2004).
43. Stamer, U.M., Stüber, F., Muders, T. & Musshoff, F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth. Analg. 107, 926–929 (2008).
44. Gasche, Y. et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 351, 2827–2831 (2004).
45. Barclay, M.L. et al. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics 13, 627–632 (2003).
46. van der Padt, A., van Schaik, R.H. & Sonneveld, P. Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms. Neth. J. Med. 64, 160–162 (2006).
47. de Leon, J., Susce, M.T., Pan, R.M., Fairchild, M., Koch, W.H. & Wedlund, P.J. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J. Clin. Psychiatry 66, 15–27 (2005).
48. Garcia–Donas, J. et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 12, 1143–1150 (2011).
49. Lauschke, V.M. & Ingelman–Sundberg, M. Precision medicine and rare genetic variants. Trends Pharmacol. Sci. 37, 85–86 (2016).
50. Machiela, M.J. & Chanock, S.J. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 31, 3555–3557 (2015).